Jasper Therapeutics, Inc. — Form 8-K
Filed July 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 82/100
What the filing says
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals and raised $132 million in concurrent preferred stock financing from multiple investors including Affinity Asset Advisors, Ikarian Capital, and Mirador Therapeutics. Kira out-licensed two assets (KP-301 and KP-402) to Mirador for $12 million upfront plus potential milestones. Post-transaction, original Jasper shareholders own 6.68%, Kira shareholders own 49.86%, and new investors own 43.46% on a fully-diluted basis; combined company has cash runway through H2 2028.
Why this rating
Transformational for $74.8M-cap company: $132M financing (176% of market cap) + pipeline consolidation + clear 18-month runway to clinical milestones substantially reshapes trajectory, though significant dilution to existing shareholders.
See more from July 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.